THE-OPEN-GROUP
25.8.2020 15:02:17 CEST | Business Wire | Press release
The Open Group , the vendor-neutral technology consortium, today announced the formation of the Open Footprint™ Forum, a Forum of The Open Group. This Forum will be focused on developing open and vendor-neutral industry standards to provide consistent and accurate measurement and reporting of environmental footprint data. The initial launch will focus on greenhouse gas (GHG) emissions data. The Forum will also cover the entire physical environmental footprint to include water, waste, and land data.
“Accurate data on environmental footprint data is critical for modern enterprises – not only for mandatory government compliance reporting and meeting customer and partner demands, but also for taking action,” said Johan Krebbers, GM Digital Emerging Technologies/VP IT Innovation at Shell . “Yet organizations face significant challenges when it comes to managing their environmental footprints such as a lack of consistency, compatibility, and interoperability throughout supply chains, as well as a shortage of standards for recording and processing this type of data.”
To meet the increasing business need for transparent and uniform reporting on environmental footprint data, the Forum will collaborate on the definition, design, and delivery of Open Footprint Data Platform standards. In the case of reporting GHG emissions, accurate data on emissions, consumptions, and base calculations will enable businesses to compare the footprint of goods and services in the value chain across every industry.
Alongside these standards, the Forum will create an open source-based system which will be accessible to all organizations. This Reference Implementation will act as the foundation for organizations to harness their own Open Footprint Data Forum implementations expected to be available from multiple parties.
“There is an urgent need to transform how we manage and report on environmental footprint data,” said Steve Nunn, President and CEO of The Open Group. “By utilizing new digital technologies and drawing on a huge amount of industry expertise, we are dedicated to enhancing reliability, credibility, and accountability around environmental data reporting to benefit businesses, governments, NGOs, and society as a whole. As an increasing number of organizations join the Forum, including operators, suppliers, and academic institutions from all industries, we are set to make substantial headway in helping businesses to better measure, monitor, and report their environmental footprints through the creation of open technology standards.”
There are currently fifteen organizations from multiple industries committed as members of the Open Footprint Forum, including Accenture, BP, Chevron, Cognite, DNV GL, Emisoft, Equinor, Halliburton, Infosys, Intel, Microsoft, Schlumberger, Shell, University of Oslo, and Wipro. Working together, member organizations will take an agile approach to the development of the Open Footprint Data Platform standards.
The Open Footprint Forum is open to all organizations. Information about the Forum and membership can be found here .
-ENDS-
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 750 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005591/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
